EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options

There is growing evidence of racial/ethnic disparities in the quality of communication
between oncologists and Latinos with cancer. These communication disparities are evidenced by
gaps in Latino's understanding of their condition and treatment options, and by worse
satisfaction with provider communication. Limited English proficiency and health literacy are
very common among Latinos, yet few interventions have been developed to help Latino cancer
patients better understand their condition and treatment options.

In this study the investigators have partnered with Latino patients, providers, and
researchers to develop a Spanish/English language intervention aimed at better informing
Latinos with advanced gastrointestinal cancers about the risks and benefits of their
chemotherapy options. Specifically, the intervention consists of a dual language,
regimen-specific suite of videos and booklets explaining the most common chemotherapy options
used to treat advanced colorectal cancer and advanced pancreatic cancer. The videos feature
Latino patients describing their experiences on treatment, as well as clinicians describing
factual information about treatment risks, benefits, and alternatives.

In this study, self-identifying Hispanic/Latino patients with metastatic colorectal cancer,
locally advanced and metastatic pancreatic cancer considering treatment with first line
chemotherapy will be randomized to the usual care, or to usual care supplemented by access to
the relevant chemotherapy educational materials. Caregivers will also be enrolled on the
study. Participants will be surveyed at baseline, 2-weeks post-treatment initiation, 2-3
months post-treatment initiation, and 4-6 months post-treatment initiation regarding their
understanding of chemotherapy risks and benefits, decisional conflict, and other metrics of
informed decision-making.

Patient Inclusion Criteria:

- Self-identify as Hispanic/Latino

- Has been diagnosed with metastatic colorectal cancer (mCRC) OR locally advanced
pancreatic cancer (LAPC) OR metastatic pancreatic cancer (mPC) AND is making a
decision regarding treatment with 1st line palliative chemotherapy

- Treating oncologist has recommended consideration of one or more of the regimens for
which we have developed chemotherapy educational (CEI) toolkits

- For mCRC: FOLFOX, FOLFOX + bevacizumab, FOLFIRI, FOLFIRI + bevacizumab

- For LAPC or mPC: FOLFIRINOX, Gemcitabine, or Gemcitabine + nab-paclitaxel

- Patients who are also considering treatment on a clinical trial of one of these
regimens +/- an investigational agent would still be eligible, so long as the
treating MD believes to the content of the CEI to be relevant to the trial
regimen.

- Planning to receive treatment at the enrolling site

- Age ≥ 21

- English or Spanish proficient

Caregiver Inclusion Criteria:

- Caregivers of eligible patient participants

- Age ≥ 21

- English or Spanish proficient

Exclusion Criteria:

- For mCRC patients: Patients with oligometastatic disease who have a definitive plan
for curative surgical resection are not eligible.

- Significant delirium/dementia as judged by the treating oncologist